{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Monastirioti A"],"funding":["Bristol Myers Squibb International Corporation (BMS)"],"pagination":["4739"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9564103"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(19)"],"pubmed_abstract":["Since circulating microRNAs (miRNAs) are involved in the modulation of the immune response, they are tested as liquid biopsy-based biomarkers in patients with NSCLC treated with immunotherapy. We analyzed the expression levels and examined the clinical significance of immunoregulatory miRNAs involved in immune checkpoint regulation (miR-34a, miR-200b, miR-200c), T-cell activity (miR-155), and the function of myeloid-derived suppressive cells (MDSCs) (miR-223) or regulatory T lymphocytes (Tregs) (miR-146a), in patients with advanced NSCLC (N = 69) treated with anti-PD-1 (Nivolumab) immunotherapy as 2nd or 3rd line of treatment therapy. Plasma levels of circulating miRNAs were analyzed by RT-qPCR before the initiation of immunotherapy. Expression of miR-34a, miR-146a, mir-200c, and miR-223 w"],"journal":["Cancers"],"pubmed_title":["Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab."],"pmcid":["PMC9564103"],"funding_grant_id":["CA209-8NX"],"pubmed_authors":["Kalapanida D","Papadaki MA","Mavroudis D","Rounis K","Agelaki S","Michaelidou K","Monastirioti A","Papadaki C"],"additional_accession":[]},"is_claimable":false,"name":"Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.","description":"Since circulating microRNAs (miRNAs) are involved in the modulation of the immune response, they are tested as liquid biopsy-based biomarkers in patients with NSCLC treated with immunotherapy. We analyzed the expression levels and examined the clinical significance of immunoregulatory miRNAs involved in immune checkpoint regulation (miR-34a, miR-200b, miR-200c), T-cell activity (miR-155), and the function of myeloid-derived suppressive cells (MDSCs) (miR-223) or regulatory T lymphocytes (Tregs) (miR-146a), in patients with advanced NSCLC (N = 69) treated with anti-PD-1 (Nivolumab) immunotherapy as 2nd or 3rd line of treatment therapy. Plasma levels of circulating miRNAs were analyzed by RT-qPCR before the initiation of immunotherapy. Expression of miR-34a, miR-146a, mir-200c, and miR-223 w","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T06:43:13.537Z","creation":"2025-04-19T06:43:13.537Z"},"accession":"S-EPMC9564103","cross_references":{"pubmed":["36230658"],"doi":["10.3390/cancers14194739"]}}